B+
Bull case
25%
Probability
Target price
$110.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
ZBH
Zimmer BiometCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$97.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$73.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-10
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+52.6
Score
AI commentary
The primary-source guidance raise and September reiteration are constructive, but the supplied recent-news list is largely about other issuers. No reliable current analyst-revision series, options skew, short-interest, employee score or social reading is available; zeroes denote unavailable data, not neutral measurements. The $89.14 anchor is the October 9 adjusted close, not a live quote. Despite the packet's positive deterministic prior and strong historical evidence quality, unproven forward adoption and commercial execution keep this a monitoring view.
RankAlpha Sentiment Codex - 2026-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventTest of raised 2026 guidanceMedium impact
Q2 organic constant-currency sales grew 4.0%, while adjusted EPS was flat year over year at $2.07. Zimmer Biomet raised its full-year organic growth outlook to 2.25%–3.25% and adjusted EPS outlook to $8.47–$8.59, then reiterated that outlook in September. December 31 is a fiscal-year-end monitoring marker, not an announced results date. [#SEC-8K-2026-08-05] Company Q2 release Company September update
2026-12-31catalystAmericas restructuring and knee-sales executionMedium impact
The September filing disclosed restructuring of Kevin Thornal's position. Three promoted leaders assumed responsibilities effective October 1 as the company sharpened its U.S. commercial and robotics focus. The operating test is whether that transition improves productivity without disruption; Q2 knee sales grew only 0.1% organically on a constant-currency basis, versus 4.0% company-wide. Year-end is a monitoring marker. [#8-K-2026-09-08] Company leadership update Company Q2 release
2027-06-30catalystROSA Shoulder adoption after clearanceMedium impact
Zimmer Biomet reported FDA 510(k) clearance and initial cases for its next-generation ROSA Shoulder system. Broader surgeon and hospital adoption—not clearance alone—is the unresolved commercial catalyst. June 30, 2027 is an analyst monitoring marker, not company launch guidance. [#SEC-8K-2026-08-05] Company Q2 release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-10 • Updated nightlySource: Internal modelMethodology